Group 1 - Morgan Stanley analyst Meta Marshall raised the price target on Coherent (COHR) to $190 from $180 while maintaining an Equal Weight rating on the shares [1] - Coherent has outperformed Lumentum (LITE) year-to-date, indicating a positive performance trend [1] - The firm expresses a more positive outlook on COHR compared to LITE ahead of the earnings report, as expectations for COHR are lower [1]

Group 1 - Citizens JMP analyst Jonathan Wolleben lowered the price target on Altimmune (ALT) to $14 from $15 while maintaining an Outperform rating on the shares [1] - The firm anticipates the oral late-breaking presentation of pemvidutide's Phase 2b data at the Liver Meeting, with 48-week data expected to be released this quarter [1]